Living Cell Technologies Ltd
ASX:LCT
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Living Cell Technologies Ltd
ASX:LCT
|
18.7m AUD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
393.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.9B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
172.7B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.7B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
86.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.4B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -16 177 900% |
| 30th Percentile | -544.7% |
| Median | -27.7% |
| 70th Percentile | 3.1% |
| Max | 3 174 540% |
Other Profitability Ratios
Living Cell Technologies Ltd
Glance View
Living Cell Technologies Ltd. is a biotechnology company, which engages in the development of treatments for implanting healthy living cells to replace or repair diseased or damaged organs for life threatening diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2004-09-01. The firm is focused on discovering and developing treatments for conditions, such as Parkinson's disease, diabetes, obesity and migraine. The firm's product pipeline consists of LP-003 for anti-obesity, LC-002 for migraine treatment and NTCELL for Parkinson's disease. Its Long-acting Pramlintide, LP-003 is a peptide drug that reduces caloric intake targeting obesity and it is also used for the treatment of diabetes. LC-002, is a receptor blocker targeting calcitonin gene-related peptide (CGRP), a neuropeptide hormone found in the nervous system. NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells targeting Parkinson's disease. NTCELL's choroid plexus cells are coated with LCT's IMMUPEL technology to protect them from attack by the immune system. The company has completed Phase I/IIa clinical trial and phase IIb trials for mid- to late-stage Parkinson's disease.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Living Cell Technologies Ltd is -5 015.8%, which is in line with its 3-year median of -5 015.8%.
Over the last 2 years, Living Cell Technologies Ltd’s Net Margin has decreased from -544.6% to -5 015.8%. During this period, it reached a low of -57 398.8% on Jun 30, 2022 and a high of -544.6% on May 30, 2021.